Biotechs Back To “New Normal,” E&Y Reports
This article was originally published in The Pink Sheet Daily
The annual report issued by Ernst & Young shows that biotech funding and revenues are back to relatively normal levels after a few years of pullback, but 2011 could be a transitional year.
You may also be interested in...
On Building A Better R&D Machine, Part 2: Pfizer’s R&D Chief Mikael Dolsten Talks Partnering Strategy And Accessing Innovation
Since ascending to the top R&D spot at the world’s largest pharmaceutical company, Mikael Dolsten has taken the lead in focusing R&D at Pfizer and optimizing its portfolio. In the second of a two-part interview with "The Pink Sheet" DAILY, Dolsten shares his thoughts on partnering and accessing external opportunities.
The 25th annual Ernst & Young report shows that biotechs have fewer exit strategies than ever and that pre-clinical stage companies still have a hard time finding financing.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.